Optimal trough concentration of teicoplanin for the treatment of methicillin-resistant Staphylococcus aureus infection: A systematic review and meta-analysis
- PMID: 33547647
- DOI: 10.1111/jcpt.13366
Optimal trough concentration of teicoplanin for the treatment of methicillin-resistant Staphylococcus aureus infection: A systematic review and meta-analysis
Abstract
What is known and objective: It has been recommended that the trough concentration (Cmin ) of teicoplanin should be maintained at ≥20 μg/ml for difficult-to-treat complicated infections caused by methicillin-resistant Staphylococcus aureus (MRSA). Conversely, Cmin of teicoplanin of at least 10 μg/ml is required for non-complicated MRSA infections. Considering the low incidence of nephrotoxicity for teicoplanin, Cmin = 15-30 μg/ml has been suggested for most MRSA infections. Thus, we assessed the clinical efficacy and adverse effects of teicoplanin at this target Cmin .
Methods: We searched electronic databases (PubMed, Cochrane Central Register of Controlled Trials and Ichushi-Web) to identify eligible studies. Studies were included if they provided the incidence of treatment success, mortality in patients with MRSA infection, and/or hepatotoxicity and nephrotoxicity according to the Cmin range.
Results and discussion: Four trials assessing clinical success (n = 299) and three studies assessing adverse effects (n = 546) were included. Cmin = 15-30 μg/ml significantly increased the probability of treatment success compared with Cmin < 15 μg/ml (odds ratio [OR] = 2.68, 95% confidence interval [CI] = 1.14-6.32, p = 0.02). The all-cause mortality rate did not differ between the groups (OR = 0.46, 95% CI = 0.13-1.61, p = 0.22). Cmin = 15-30 μg/ml did not increase the risks of nephrotoxicity (OR = 0.91, 95% CI = 0.49-1.69, p = 0.76) or hepatotoxicity (OR = 0.67, 95% CI = 0.18-2.44, p = 0.54).
What is new and conclusion: Teicoplanin therapy using a Cmin target of 15-30 μg/ml is likely to be associated with better clinical responses than Cmin < 15 μg/ml without increasing the risk of adverse effects.
Keywords: gram-positive bacteria; meta-analysis; methicillin-resistant Staphylococcus aureus; teicoplanin; therapeutic drug monitoring; trough concentration.
© 2021 John Wiley & Sons Ltd.
Similar articles
-
Clinical efficacy and safety in patients treated with teicoplanin with a target trough concentration of 20 μg/mL using a regimen of 12 mg/kg for five doses within the initial 3 days.BMC Pharmacol Toxicol. 2020 Jul 8;21(1):50. doi: 10.1186/s40360-020-00424-3. BMC Pharmacol Toxicol. 2020. PMID: 32641110 Free PMC article.
-
Enhanced loading regimen of teicoplanin is necessary to achieve therapeutic pharmacokinetics levels for the improvement of clinical outcomes in patients with renal dysfunction.Eur J Clin Microbiol Infect Dis. 2016 Sep;35(9):1501-9. doi: 10.1007/s10096-016-2691-z. Epub 2016 Jun 9. Eur J Clin Microbiol Infect Dis. 2016. PMID: 27278654
-
Significance of High Trough Concentration of Teicoplanin in the Treatment of Methicillin-Resistant Staphylococcus aureus Infection.Chemotherapy. 2014;60(4):274-8. doi: 10.1159/000381634. Epub 2015 Apr 25. Chemotherapy. 2014. PMID: 25926288
-
The monitoring of vancomycin: a systematic review and meta-analyses of area under the concentration-time curve-guided dosing and trough-guided dosing.BMC Infect Dis. 2021 Feb 6;21(1):153. doi: 10.1186/s12879-021-05858-6. BMC Infect Dis. 2021. PMID: 33549035 Free PMC article.
-
Linezolid versus vancomycin or teicoplanin for nosocomial pneumonia: meta-analysis of randomised controlled trials.Eur J Clin Microbiol Infect Dis. 2013 Sep;32(9):1121-8. doi: 10.1007/s10096-013-1867-z. Epub 2013 Apr 10. Eur J Clin Microbiol Infect Dis. 2013. PMID: 23568605 Review.
Cited by
-
Dose Optimization of Teicoplanin for Critically Ill Patients With Renal Dysfunction and Continuous Renal Replacement Therapy: Experience From a Prospective Interventional Study.Front Pharmacol. 2022 Mar 8;13:817401. doi: 10.3389/fphar.2022.817401. eCollection 2022. Front Pharmacol. 2022. PMID: 35350761 Free PMC article.
-
Trends in teicoplanin loading dose implementation from 2010 to 2019 and evaluation of safety and efficacy factors: a retrospective cohort study based on a Japanese administrative claims database.J Pharm Health Care Sci. 2023 Nov 1;9(1):35. doi: 10.1186/s40780-023-00304-y. J Pharm Health Care Sci. 2023. PMID: 37908001 Free PMC article.
-
Clinical practice guidelines for therapeutic drug monitoring of teicoplanin: a consensus review by the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring.J Antimicrob Chemother. 2022 Mar 31;77(4):869-879. doi: 10.1093/jac/dkab499. J Antimicrob Chemother. 2022. PMID: 35022752 Free PMC article.
-
Accuracy of Therapeutic Drug Monitoring of Teicoplanin at the Onset of Febrile Neutropenia.Medicina (Kaunas). 2023 Apr 13;59(4):758. doi: 10.3390/medicina59040758. Medicina (Kaunas). 2023. PMID: 37109716 Free PMC article.
-
Methicillin-resistant Staphylococcus aureus Infection and its Health Perspective: A Review.Curr Pharm Biotechnol. 2025;26(9):1331-1347. doi: 10.2174/0113892010310231240529075731. Curr Pharm Biotechnol. 2025. PMID: 38847161 Review.
References
REFERENCES
-
- Grundmann H, Aanensen DM, van den Wijngaard CC, et al. Geographic distribution of Staphylococcus aureus causing invasive infections in Europe: a molecular-epidemiological analysis. PLoS Medicine. 2010;7:e1000215.
-
- Song J-H, Hsueh P-R, Chung DR, et al. Spread of methicillin-resistant Staphylococcus aureus between the community and the hospitals in Asian countries: an ANSORP study. J Antimicrob Chemother. 2011;66:1061-1069.
-
- Gould IM, David MZ, Esposito S, et al. New insights into meticillin-resistant Staphylococcus aureus (MRSA) pathogenesis, treatment and resistance. Int J Antimicrob Agents. 2012;39:96-104.
-
- Hagihara M, Kimura M, Hasegawa T, et al. Exploration of optimal teicoplanin dosage based on pharmacokinetic parameters for the treatment of intensive care unit patients infected with methicillin-resistant Staphylococcus aureus. J Infect Chemother. 2012;18:10-16.
-
- Kern WV. Management of Staphylococcus aureus bacteremia and endocarditis: progresses and challenges. Curr Opin Infect Dis. 2010;23:346-358.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical